IOLCP Q4 FY26 PAT Surges 68% YoY to ₹53.2 Crore

IOL Chemicals reported Q4 FY26 revenue of ₹619.5 Cr, up 17.4% YoY, with PAT surging 68.2% to ₹53.2 Cr.
Full-year FY26 revenue reached ₹2,319.1 Cr, an 11.5% increase, while EBITDA grew 29.3% to ₹290.4 Cr.
The company's non-Ibuprofen pharmaceuticals business expanded to 37% of segment revenue, driven by products like Paracetamol and Metformin.
Strategic initiatives include backward integration, a 101-acre land acquisition for expansion, and holding 14 DMFs with USFDA for regulated market growth.